HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Yan Zhao; Cheng Xing; Yating Deng; Can Ye; Hongling Peng

doi:10.1016/j.gendis.2023.02.039

您当前的位置：

首页 >

文章列表页 >

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Review Articles | 更新时间：2024-02-04

- HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies
- HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies
- Genes & Diseases 2024年1卷第1期页码：234-251
- 作者机构：
  
  1. Department of Hematology, The Second Xiangya Hospital, Central South University,Hunan,Changsha,China,410011
  2. Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University,Hunan,Changsha,China,410011
  3. Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, The Second Xiangya Hospital, Central South University,Hunan,Changsha,China,410011
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.039
  中图分类号：
- 纸质出版日期：2024，
  
  网络出版日期：2024-1-1，
扫描看全文
HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies[J]. Genes & Diseases, 2024,1(1):234-251.

Yan Zhao, Cheng Xing, Yating Deng, et al. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies[J]. Genes & Diseases, 2024,1(1):234-251.
HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies[J]. Genes & Diseases, 2024,1(1):234-251. DOI： 10.1016/j.gendis.2023.02.039.

Yan Zhao, Cheng Xing, Yating Deng, et al. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies[J]. Genes & Diseases, 2024,1(1):234-251. DOI： 10.1016/j.gendis.2023.02.039.

摘要

Abstract

The hypoxic microenvironment is an essential characteristic of most malignant tumors. Notably

hypoxia-inducible factor-1 alpha (HIF-1α) is a key regulatory factor of cellular adaptation to hypoxia

and many critical pathways are correlated with the biological activity of organisms via HIF-1α. In the intra-tumoral hypoxic environment

HIF-1α is highly expressed and contributes to the malignant progression of tumors

which in turn results in a poor prognosis in patients. Recently

it has been indicated that HIF-1α involves in various critical processes of life events and tumor development via regulating the expression of HIF-1α target genes

such as cell proliferation and apoptosis

angiogenesis

glucose metabolism

immune response

therapeutic resistance

etc

. Apart from solid tumors

accumulating evidence has revealed that HIF-1α is also closely associated with the development and progression of hematological malignancies

such as leukemia

lymphoma

and multiple myeloma. Targeted inhibition of HIF-1α can facilitate an increased sensitivity of patients with malignancies to relevant therapeutic agents. In the review

we elaborated on the basic structure and biological functions of HIF-1α and summarized their current role in various malignancies. It is expected that they will have future potential for targeted therapy.

关键词

Keywords

AngiogenesisHematological malignanciesHypoxia-inducible factor-1 alpha (HIF-1α)Immune escapeTargeted therapy

references

1 G.L. SemenzaHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy Trends Pharmacol Sci, 33 (4) (2012), pp. 207-214

2 G.L. Wang, B.H. Jiang, E.A. Rue, et al.Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci U S A, 92 (12) (1995), pp. 5510-5514

3 J.W. Lee, S.H. Bae, J.W. Jeong, et al.Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions Exp Mol Med, 36 (1) (2004), pp. 1-12

4 A.J. Levine, N.A. Jenkins, N.G. CopelandThe roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters Cancer Cell, 35 (1) (2019), pp. 10-15

5 D. Rodriguez-Abreu, A. Bordoni, E. ZuccaEpidemiology of hematological malignancies Ann Oncol, 18 (Suppl 1) (2007), pp. i3-i8

6 L. Adès, R. Itzykson, P. FenauxMyelodysplastic syndromes Lancet, 383 (9936) (2014), pp. 2239-2252

7 D. Bhojwani, C.H. PuiRelapsed childhood acute lymphoblastic leukaemia Lancet Oncol, 14 (6) (2013), pp. e205-e217

8 L. Duca, M.D. Cappellini, D. Baronciani, et al.Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload Am J Hematol, 93 (9) (2018), pp. E250-E252

9 M. Najafi, J. Majidpoor, H. Toolee, et al.The current knowledge concerning solid cancer and therapy J Biochem Mol Toxicol, 35 (11) (2021), Article e22900

10 D.M. Gilkes, G.L. Semenza, D. WirtzHypoxia and the extracellular matrix: drivers of tumour metastasis Nat Rev Cancer, 14 (6) (2014), pp. 430-439

11 K. Rouault-Pierre, A. Hamilton, D. BonnetEffect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact Expet Opin Biol Ther, 16 (4) (2016), pp. 463-476

12 H. Ledford, E. CallawayBiologists who decoded how cells sense oxygen win medicine Nobel Nature, 574 (7777) (2019), pp. 161-162

13 G.L. Semenza, G.L. WangA nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol Cell Biol, 12 (12) (1992), pp. 5447-5454

14 Z. Liu, Z. Wu, Y. Fan, et al.An overview of biological research on hypoxia-inducible factors (HIFs) Endokrynol Pol, 71 (5) (2020), pp. 432-440

15 J. Korbecki, D. Simińska, M. Gąssowska-Dobrowolska, et al.Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-κB activation: a review of the molecular mechanisms Int J Mol Sci, 22 (19) (2021), Article 10701

16 T. Tanaka, M. Wiesener, W. Bernhardt, et al.The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction Biochem J, 424 (1) (2009), pp. 143-151

17 P. Zhang, Q. Yao, L. Lu, et al.Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia Cell Rep, 6 (6) (2014), pp. 1110-1121

18 S.L. Yang, C. Wu, Z.F. Xiong, et al.Progress on hypoxia-inducible factor-3: its structure, gene regulation and biological function (Review) Mol Med Rep, 12 (2) (2015), pp. 2411-2416

19 W. Luo, H. Hu, R. Chang, et al.Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell, 145 (5) (2011), pp. 732-744

20 V.L. Dengler, M.D. Galbraith, J.M. EspinosaTranscriptional regulation by hypoxia inducible factors Crit Rev Biochem Mol Biol, 49 (1) (2014), pp. 1-15

21 J.S. Lee, E.Y. Kim, K. Iwabuchi, et al.Molecular and functional characterization of aryl hydrocarbon receptor nuclear translocator 1 (ARNT1) and ARNT2 in chicken (Gallus gallus) Comp Biochem Physiol C Toxicol Pharmacol, 153 (3) (2011), pp. 269-279

22 H. Reyes, S. Reisz-Porszasz, O. HankinsonIdentification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor Science, 256 (5060) (1992), pp. 1193-1195

23 Q. Ke, M. CostaHypoxia-inducible factor-1 (HIF-1) Mol Pharmacol, 70 (5) (2006), pp. 1469-1480

24 P.J.A. Erbel, P.B. Card, O. Karakuzu, et al.Structural basis for PAS domain heterodimerization in the basic helix–loop–helix–PAS transcription factor hypoxia-inducible factor Proc Natl Acad Sci U S A, 100 (26) (2003), pp. 15504-15509

25 A. Chapman-Smith, J.K. Lutwyche, M.L. WhitelawContribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators J Biol Chem, 279 (7) (2004), pp. 5353-5362

26 N. Albadari, S. Deng, W. LiThe transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy Expet Opin Drug Discov, 14 (7) (2019), pp. 667-682

27 B.H. Jiang, E. Rue, G.L. Wang, et al.Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 J Biol Chem, 271 (30) (1996), pp. 17771-17778

28 L.E. Huang, J. Gu, M. Schau, et al.Regulation of hypoxia-inducible factor 1alpha is mediated by an O2- dependent degradation domain via the ubiquitin-proteasome pathway Proc Natl Acad Sci U S A, 95 (14) (1998), pp. 7987-7992

29 B.H. Jiang, J.Z. Zheng, S.W. Leung, et al.Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension J Biol Chem, 272 (31) (1997), pp. 19253-19260

30 S.J. Freedman, Z.Y.J. Sun, F. Poy, et al.Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha Proc Natl Acad Sci U S A, 99 (8) (2002), pp. 5367-5372

31 P.C. Mahon, K. Hirota, G.L. SemenzaFIH-1:a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev, 15 (20) (2001), pp. 2675-2686

32 W.G. Kaelin, P.J. RatcliffeOxygen sensing by metazoans: the central role of the HIF hydroxylase pathway Mol Cell, 30 (4) (2008), pp. 393-402

33 P. Jaakkola, D.R. Mole, Y.M. Tian, et al.Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2- regulated prolyl hydroxylation Science, 292 (5516) (2001), pp. 468-472

34 W.C. Hon, M.I. Wilson, K. Harlos, et al.Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL Nature, 417 (6892) (2002), pp. 975-978

35 D. Lando, D.J. Peet, J.J. Gorman, et al.FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor Genes Dev, 16 (12) (2002), pp. 1466-1471

36 S.A. Dames, M. Martinez-Yamout, R.N. De Guzman, et al.Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response Proc Natl Acad Sci U S A, 99 (8) (2002), pp. 5271-5276

37 A.J. Majmundar, W.J. Wong, M.C. SimonHypoxia-inducible factors and the response to hypoxic stress Mol Cell, 40 (2) (2010), pp. 294-309

38 S.J. Kierans, C.T. TaylorRegulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology J Physiol, 599 (1) (2021), pp. 23-37

39 P.C. Ho, J. Bihuniak, A. MacIntyre, et al.Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses Cell, 162 (6) (2015), pp. 1217-1228

40 S.N. Greer, J.L. Metcalf, Y. Wang, et al.The updated biology of hypoxia-inducible factor EMBO J, 31 (11) (2012), pp. 2448-2460

41 S.Y. Tam, V.W.C. Wu, H.K.W. LawHypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond Front Oncol, 10 (2020), p. 486

42 Y.K. ChoiA positive circuit of VEGF increases Glut-1 expression by increasing HIF-1α gene expression in human retinal endothelial cells Arch Pharm Res (Seoul), 40 (12) (2017), pp. 1433-1442

43 T. Suzuki, S. Minagawa, T. Yamazaki, et al.Loss of hypoxia inducible factor-1α aggravates γδ T-cell-mediated inflammation during acetaminophen-induced liver injury Hepatol Commun, 2 (5) (2018), pp. 571-581

44 T. Chen, K. Li, Z. Liu, et al.WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways Mol Ther, 29 (6) (2021), pp. 2134-2150

45 H. Tian, T. Qiang, J. Wang, et al.Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1α axis Bioengineered, 12 (2) (2021), pp. 11898-11908

46 D. Peng, T. Wu, J. Wang, et al.microRNA-671-5p reduces tumorigenicity of ovarian cancer via suppressing HDAC5 and HIF-1α expression Chem Biol Interact, 355 (2022), Article 109780

47 A. Akil, A.K. Gutiérrez-García, R. Guenter, et al.Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: an update and prospective Front Cell Dev Biol, 9 (2021), Article 642352

48 R. Kopan, M.X.G. IlaganThe canonical Notch signaling pathway: unfolding the activation mechanism Cell, 137 (2) (2009), pp. 216-233

49 S.K.J. Landor, U. LendahlThe interplay between the cellular hypoxic response and Notch signaling Exp Cell Res, 356 (2) (2017), pp. 146-151

50 J.O. Misiorek, A. Przybyszewska-Podstawka, J. Kałafut, et al.Context matters: Notch signatures and pathway in cancer progression and metastasis Cells, 10 (2021), p. 94

51 I. Amelio, M. Mancini, V. Petrova, et al.p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression Proc Natl Acad Sci U S A, 115 (46) (2018), pp. E10869-E10878

52 I. Amelio, G. MelinoThe p53 family and the hypoxia-inducible factors (HIFs):determinants of cancer progression Trends Biochem Sci, 40 (8) (2015), pp. 425-434

53 B. Keith, R.S. Johnson, M.C. SimonHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression Nat Rev Cancer, 12 (1) (2012), pp. 9-22

54 K. Xu, Y. Zhan, Z. Yuan, et al.Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop Mol Ther, 27 (10) (2019), pp. 1810-1824

55 M. Kilic, H. Kasperczyk, S. Fulda, et al.Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance Oncogene, 26 (14) (2007), pp. 2027-2038

56 J. Feng, J. Zhan, S. MaLRG1 promotes hypoxia-induced cardiomyocyte apoptosis and autophagy by regulating hypoxia-inducible factor-1α Bioengineered, 12 (1) (2021), pp. 8897-8907

57 H. Semba, N. Takeda, T. Isagawa, et al.HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity Nat Commun, 7 (2016), Article 11635

58 G. Wang, Y. Li, Z. Yang, et al.ROS mediated EGFR/MEK/ERK/HIF-1α Loop Regulates Glucose metabolism in pancreatic cancer Biochem Biophys Res Commun, 500 (4) (2018), pp. 873-878

59 Y. Hu, H. Mu, Z. DengThe transcription factor TEAD4 enhances lung adenocarcinoma progression through enhancing PKM2 mediated glycolysis Cell Biol Int, 45 (10) (2021), pp. 2063-2073

60 B. Desvergne, W. WahliPeroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev, 20 (5) (1999), pp. 649-688

61 A. Chatterjee, P. Mondal, S. Ghosh, et al.PPARγ regulated CIDEA affects pro-apoptotic responses in glioblastoma Cell Death Dis, 1 (2015), Article 15038

62 J. Feng, W. Dai, Y. Mao, et al.Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis J Exp Clin Cancer Res, 39 (2020), p. 24

63 C.J. Peach, V.W. Mignone, M.A. Arruda, et al.Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2 Int J Mol Sci, 19 (4) (2018), p. 1264

64 G. Peng, Y. LiuHypoxia-inducible factors in cancer stem cells and inflammation Trends Pharmacol Sci, 36 (6) (2015), pp. 374-383

65 N.M. Santio, P.J. KoskinenPIM kinases: from survival factors to regulators of cell motility Int J Biochem Cell Biol, 93 (2017), pp. 74-85

66 A.L. Casillas, S.S. Chauhan, R.K. Toth, et al.Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors Oncogene, 40 (32) (2021), pp. 5142-5152

67 C. Fang, L. Dai, C. Wang, et al.Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer Mol Oncol, 15 (12) (2021), pp. 3513-3526

68 G. Sun, Y. Li, Y. Peng, et al.Identification of a five-gene signature with prognostic value in colorectal cancer J Cell Physiol, 234 (4) (2019), pp. 3829-3836

69 J.W. Liu, F. Yu, Y.F. Tan, et al.Profiling of tumor microenvironment components identifies five stroma-related genes with prognostic implications in colorectal cancer Cancer Biother Radiopharm, 37 (10) (2022), pp. 882-892

70 M.Z. Noman, M. Hasmim, A. Lequeux, et al.Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges Cells, 8 (9) (2019), p. 1083

71 H. Zhang, H. Lu, L. Xiang, et al.HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells Proc Natl Acad Sci U S A, 112 (45) (2015), pp. E6215-E6223

72 J. Deng, J. Li, A. Sarde, et al.Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment Cancer Immunol Res, 7 (7) (2019), pp. 1079-1090

73 Z. Deng, Y.J. Teng, Q. Zhou, et al.Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma World J Gastrointest Oncol, 13 (11) (2021), pp. 1725-1740

74 H. Wei, A. Xie, J. Li, et al.PD-1+ CD4 T cell immune response is mediated by HIF-1α/NFATc1 pathway after P. yoelii infection Front Immunol, 13 (2022), Article 942862

75 C. Lin, S.W. Lai, C.K. Shen, et al.Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells Environ Toxicol, 36 (12) (2021), pp. 2551-2561

76 M. Osada-Oka, H. Kuwamura, R. Imamiya, et al.Suppression of the doxorubicin response by hypoxia-inducible factor-1α is strictly dependent on oxygen concentrations under hypoxic conditions Eur J Pharmacol, 920 (2022), Article 174845

77 S. Soni, Y.S. PadwadHIF-1 in cancer therapy: two decade long story of a transcription factor Acta Oncol, 56 (4) (2017), pp. 503-515

78 G.L. SemenzaHypoxia-inducible factors in physiology and medicine Cell, 148 (3) (2012), pp. 399-408

79 G.L. SemenzaTargeting HIF-1 for cancer therapy Nat Rev Cancer, 3 (10) (2003), pp. 721-732

80 L. Schito, G.L. SemenzaHypoxia-inducible factors: master regulators of cancer progression Trends Cancer, 2 (12) (2016), pp. 758-770

81 G. Multhoff, P. VaupelHypoxia compromises anti-cancer immune responses Adv Exp Med Biol, 1232 (2020), pp. 131-143

82 H. Lu, Y. Lyu, L. Tran, et al.HIF-1 recruits NANOG as a coactivator for TERT gene transcription in hypoxic breast cancer stem cells Cell Rep, 36 (13) (2021), Article 109757

83 Z. Song, T. Liu, J. Chen, et al.HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib Cancer Lett, 460 (2019), pp. 96-107

84 W. Feng, T. Xue, S. Huang, et al.HIF-1α promotes the migration and invasion of hepatocellular carcinoma cells via the IL-8-NF-κB axis Cell Mol Biol Lett, 23 (2018), p. 26

85 Y. Zhang, L. Jiang, N. Qin, et al.hCINAP is potentially a direct target gene of HIF-1 and is required for hypoxia-induced EMT and apoptosis in cervical cancer cells Biochem Cell Biol, 99 (2) (2021), pp. 203-213

86 Y.A. Tang, Y.F. Chen, Y. Bao, et al.Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer Proc Natl Acad Sci U S A, 115 (26) (2018), pp. E5990-E5999

87 K. Huang, X. Zhang, Y. Hao, et al.Hypoxia tumor microenvironment activates GLI2 through HIF-1α and TGF-β2 to promote chemotherapy resistance of colorectal cancer Comput Math Methods Med, 2022 (2022), Article 2032895

88 S. Huang, P. Qi, T. Zhang, et al.The HIF-1α/miR-224-3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia-induced protective autophagy in glioblastoma and astrocytoma Oncol Rep, 41 (3) (2019), pp. 1759-1768

89 Z. Xiang, X. Deng, W. He, et al.Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy Ann Med, 54 (1) (2022), pp. 1357-1371

90 R. Jaidee, S. Kongpetch, L. Senggunprai, et al.Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways Naunyn-Schmiedeberg’s Arch Pharmacol, 393 (9) (2020), pp. 1681-1690

91 J. Gaudichon, H. Jakobczyk, L. Debaize, et al.Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues Blood Rev, 36 (2019), pp. 40-56

92 H. You, D. Wang, L. Wei, et al.Deferoxamine inhibits acute lymphoblastic leukemia progression through repression of ROS/HIF-1 α, Wnt/β-catenin, and p38MAPK/ERK pathways JAMA Oncol, 2022 (2022), Article 8281267

93 G. Antonio-Andres, G.U. Martinez-Ruiz, M. Morales-Martinez, et al.Transcriptional regulation of Yin-Yang 1 expression through the hypoxia inducible factor-1 in pediatric acute lymphoblastic leukemia Int J Mol Sci, 23 (3) (2022), p. 1728

94 L. Fahy, J. Calvo, S. Chabi, et al.Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop Blood Adv, 5 (2) (2021), pp. 513-526

95 C. Vitale, V. Griggio, C. Riganti, et al.Targeting HIF-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in CLL Cancers, 13 (12) (2021), p. 2883

96 V. Griggio, C. Vitale, M. Todaro, et al.HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia Haematologica, 105 (4) (2020), pp. 1042-1054

97 D.Y. Yosifov, I. Idler, N. Bhattacharya, et al.Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL Leukemia, 34 (1) (2020), pp. 115-127

98 R. Valsecchi, N. Coltella, D. Magliulo, et al.EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine Open Biol, 10 (5) (2020), Article 190262

99 Y. Zhu, Z. Liu, Y. Wan, et al.PARP14 promotes the growth and glycolysis of acute myeloid leukemia cells by regulating HIF-1α expression Clin Immunol, 242 (2022), Article 109094

100 L. Li, L. Zhao, J. Man, et al.CXCL2 benefits acute myeloid leukemia cells in hypoxia Int J Lab Hematol, 43 (5) (2021), pp. 1085-1092

101 B. Zhu, S. Pan, J. Liu, et al.HIF-1α forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells Cell Biol Int, 44 (2) (2020), pp. 456-466

102 Y. Wang, Y. Liu, C. Bailey, et al.Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin Oncogene, 39 (14) (2020), pp. 3015-3027

103 A. Waclawiczek, A. Hamilton, K. Rouault-Pierre, et al.Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia J Clin Invest, 130 (6) (2020), pp. 3038-3050

104 M. Tsubaki, T. Takeda, T. Matsuda, et al.Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells BMB Rep, 56 (2) (2023), pp. 78-83

105 Y. Zhang, H. Chen, Y. Shen, et al.Combined effects of 2-methoxyestradiol (hypoxia-inducible factor 1 α inhibitor) and dasatinib (a second-generation tyrosine kinase inhibitor) on chronic myelocytic leukemia cells J Immunol Res, 2022 (2022), Article 6324326

106 B. Guo, A.D. Pomicter, F. Li, et al.Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance Proc Natl Acad Sci U S A, 118 (51) (2021), Article e2107220118

107 S.G. Rawat, R.K. Tiwari, P.K. Jaiswara, et al.Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism Apoptosis, 27 (7) (2022), pp. 606-618

108 Y. Goel, S. Yadav, S.K. Pandey, et al.Methyl jasmonate cytotoxicity and chemosensitization of T cell lymphoma in vitro is facilitated by HK 2, HIF-1α, and Hsp70: implication of altered regulation of cell survival, pH homeostasis, mitochondrial functions Front Pharmacol, 12 (2021), Article 628329

109 B. Wang, K. Li, H. Wang, et al.Systemic chemotherapy promotes HIF-1α-mediated glycolysis and IL-17F pathways in cutaneous T-cell lymphoma Exp Dermatol, 29 (10) (2020), pp. 987-992

110 A. Russignan, G. Dal Collo, A. Bagnato, et al.Targeting the endothelin-1 receptors curtails tumor growth and angiogenesis in multiple myeloma Front Oncol, 10 (2020), Article 600025

111 M. Wang, H.Y. Zhao, J.L. Zhang, et al.Dysregulation of LncRNA ANRIL mediated by miR-411–3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α Exp Cell Res, 396 (1) (2020), Article 112280

112 J. Zou, P. Li, F. Lu, et al.Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells J Hematol Oncol, 6 (2013), p. 3

113 G. Antonio-Andrés, J. Rangel-Santiago, B. Tirado-Rodríguez, et al.Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (MDR1) gene Leuk Lymphoma, 59 (11) (2018), pp. 2628-2638

114 M. SeiffertHIF-1α: a potential treatment target in chronic lymphocytic leukemia Haematologica, 105 (4) (2020), pp. 856-858

115 R. Valsecchi, N. Coltella, D. Belloni, et al.HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment Blood, 127 (16) (2016), pp. 1987-1997

116 S. Serra, T. Vaisitti, V. Audrito, et al.Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment Blood Adv, 1 (1) (2016), pp. 47-61

117 B. Zhu, W. Zhong, X. Cao, et al.Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice Sci Transl Med, 14 (629) (2022), Article eabh2548

118 A.M. Abdul-Aziz, M.S. Shafat, Y. Sun, et al.HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia Oncogene, 37 (20) (2018), pp. 2676-2686

119 N. Coltella, S. Percio, R. Valsecchi, et al.HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse EMBO Mol Med, 6 (5) (2014), pp. 640-650

120 T. Badar, D.R. Handisides, J.M. Benito, et al.Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia Am J Hematol, 91 (8) (2016), pp. 800-805

121 T. Velasco-Hernandez, S. Soneji, I. Hidalgo, et al.Hif-1α deletion may lead to adverse treatment effect in a mouse model ofMLL-AF9-driven AML Stem Cell Rep, 12 (1) (2019), pp. 112-121

122 T. Velasco-Hernandez, A. Hyrenius-Wittsten, M. Rehn, et al.HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia Blood, 124 (24) (2014), pp. 3597-3607

123 R. Nehme, R. Hallal, M. El Dor, et al.Repurposing of acriflavine to target chronic myeloid leukemia treatment Curr Med Chem, 28 (11) (2021), pp. 2218-2233

124 F. Monteleone, S. Taverna, R. Alessandro, et al.SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1α axis J Exp Clin Cancer Res, 37 (2018), p. 170

125 F. Zhao, A. Mancuso, T.V. Bui, et al.Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming Oncogene, 29 (20) (2010), pp. 2962-2972

126 S. Li, C. Qiao, L. Yang, et al.Fumarate hydratase deficiency induces chronic myeloid leukemia progression Transl Cancer Res, 8 (2) (2019), pp. 592-602

127 J. Huang, Z. Lu, Y. Xiao, et al.Inhibition of Siah2 ubiquitin ligase by vitamin K3 attenuates chronic myeloid leukemia chemo-resistance in hypoxic microenvironment Med Sci Mon Int Med J Exp Clin Res, 24 (2018), pp. 727-735

128 H. Chen, Y. Shen, F. Gong, et al.HIF-α promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression Cell Biochem Biophys, 72 (1) (2015), pp. 179-183

129 J.F. Larouche, F. Berger, C. Chassagne-Clément, et al.Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome J Clin Oncol, 28 (12) (2010), pp. 2094-2100

130 A.M. Evens, L.H. Sehn, P. Farinha, et al.Hypoxia-inducible factor-1{alpha}expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP J Clin Oncol, 28 (6) (2010), pp. 1017-1024

131 J. Chiche, S. Pommier, M. Beneteau, et al.GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α Leukemia, 29 (5) (2015), pp. 1163-1176

132 M. Nakashima, M. Watanabe, K. Nakano, et al.Differentiation of Hodgkin lymphoma cells by reactive oxygen species and regulation by heme oxygenase-1 through HIF-1α Cancer Sci, 112 (6) (2021), pp. 2542-2555

133 P. Shrestha, D.A. Davis, R.P. Veeranna, et al.Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma PLoS Pathog, 13 (9) (2017), Article e1006628

134 M. Tsubaki, T. Takeda, Y. Tomonari, et al.Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB Lab Invest, 99 (1) (2019), pp. 72-84

135 Z. Chen, T.C. Lin, X. Bi, et al.TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1α stabilization Leukemia, 33 (2) (2019), pp. 469-486

136 M.F. Clarke, J.E. Dick, P.B. Dirks, et al.Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res, 66 (19) (2006), pp. 9339-9344

137 W.W. Tong, G.H. Tong, Y. LiuCancer stem cells and hypoxia-inducible factors (Review) Int J Oncol, 53 (2) (2018), pp. 469-476

138 B. Beck, C. BlanpainUnravelling cancer stem cell potential Nat Rev Cancer, 13 (10) (2013), pp. 727-738

139 D. Bonnet, J.E. DickHuman acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med, 3 (7) (1997), pp. 730-737

140 M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, et al.Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci U S A, 100 (7) (2003), pp. 3983-3988

141 J.H. Lee, W. Hur, S.W. Hong, et al.ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α Oncol Rep, 37 (2) (2017), pp. 813-822

142 Q.Y. Shi, S.J. Zhang, L. Liu, et al.Sevoflurane promotes the expansion of glioma stem cells through activation of hypoxia-inducible factors in vitro Br J Anaesth, 114 (5) (2015), pp. 825-830

143 A. Soeda, M. Park, D. Lee, et al.Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha Oncogene, 28 (45) (2009), pp. 3949-3959

144 S. Zhang, X. Luo, F. Wan, et al.The roles of hypoxia-inducible factors in regulating neural stem cells migration to glioma stem cells and determining their fates Neurochem Res, 37 (12) (2012), pp. 2659-2666

145 G.L. SemenzaRegulation of the breast cancer stem cell phenotype by hypoxia-inducible factors Clin Sci (Lond), 129 (12) (2015), pp. 1037-1045

146 M. Deynoux, N. Sunter, O. Hérault, et al.Hypoxia and hypoxia-inducible factors in leukemias Front Oncol, 6 (2016), p. 41

147 J.M. Heddleston, Q. Wu, M. Rivera, et al.Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential Cell Death Differ, 19 (3) (2012), pp. 428-439

148 J.C. Sun, F. He, W. Yi, et al.High expression of HIF-2α and its anti-radiotherapy effect in lung cancer stem cells Genet Mol Res, 14 (4) (2015), pp. 18110-18120

149 S. Hao, F. Li, P. Jiang, et al.Effect of chronic intermittent hypoxia-induced HIF-1α/ATAD2 expression on lung cancer stemness Cell Mol Biol Lett, 27 (2022), p. 44

150 R. Vadde, S. Vemula, R. Jinka, et al.Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer Crit Rev Oncol Hematol, 113 (2017), pp. 22-27

151 S. Thomas, M.A. Harding, S.C. Smith, et al.CD24 is an effector of HIF-1-driven primary tumor growth and metastasis Cancer Res, 72 (21) (2012), pp. 5600-5612

152 S. Banerjee, A. SalujaMinnelide, a novel drug for pancreatic and liver cancer Pancreatology, 15 (4) (2015), pp. S39-S43

153 M.Y. Koh, T. Spivak-Kroizman, S. Venturini, et al.Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha Mol Cancer Therapeut, 7 (1) (2008), pp. 90-100

154 V. Infantino, A. Santarsiero, P. Convertini, et al.Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target Int J Mol Sci, 22 (11) (2021), p. 5703

155 J. Liu, C. Zhang, Y. Zhao, et al.Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression Nat Commun, 8 (1) (2017), p. 1823

156 C.M. Bailey, Y. Liu, G. Peng, et al.Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer Nanomedicine, 29 (2020), Article 102278

157 B. Parmakhtiar, R.A. Burger, J.H. Kim, et al.HIF inactivation of p53 in ovarian cancer can be reversed by topotecan, restoring cisplatin and paclitaxel sensitivity Mol Cancer Res, 17 (8) (2019), pp. 1675-1686

158 H. Hu, X.K. Miao, J.Y. Li, et al.YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells Eur J Pharmacol, 874 (2020), Article 172961

159 E. Pham, M.J. Birrer, S. Eliasof, et al.Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer Clin Cancer Res, 21 (4) (2015), pp. 808-818

160 K.T. Schmidt, C.J. Peer, A.D.R. Huitema, et al.Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma J Pharm Biomed Anal, 181 (2020), Article 113073

161 Y. Mo, Y. Zhang, Y. Zhang, et al.Nickel nanoparticle-induced cell transformation: involvement of DNA damage and DNA repair defect through HIF-1α/miR-210/Rad52 pathway J Nanobiotechnol, 19 (2021), p. 370

162 S.Y. Oh, J.Y. Seok, Y.S. Choi, et al.The histone methyltransferase inhibitor BIX01294 inhibits HIF-1α stability and angiogenesis Mol Cell, 38 (6) (2015), pp. 528-534

163 Y. Li, F. Wang, X. Chen, et al.Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups Curr Top Med Chem, 19 (3) (2019), pp. 223-241

164 M.H. Kim, T.H. Lee, J.S. Lee, et al.Hif-1α inhibitors could successfully inhibit the progression of differentiated thyroid cancer in vitro Pharmaceuticals, 13 (9) (2020), p. 208

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

The journey towards physiology and pathology: Tracing the path of neuregulin 4

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities

Mechanistic insight into lysyl oxidase in vascular remodeling and angiogenesis

Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies